SCHEMBL23207919

SCHEMBL23207919

O=C(Nc1ccc(C(F)(F)F)cc1)Nc1c[nH]c2ccc(-c3ccc(F)cc3F)cc12

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 4/20 0.60
▸ MTOR P42345 1/20 0.46
▸ IGF1R P08069 5/20 0.46
▸ CNR1 P21554 1/20 0.46
▸ RIPK1 Q13546 5/20 0.45
▸ EPHX2 P34913 1/20 0.44
▸ IKBKB O14920 1/20 0.43
▸ CHUK O15111 1/20 0.43
▸ LYN P07948 1/20 0.43
▸ SYK P43405 1/20 0.43
▸ MAPK8 P45983 1/20 0.43
▸ MAPK10 P53779 1/20 0.43
▸ KIT P10721 1/20 0.42
▸ KDR P35968 1/20 0.42
▸ FLT3 P36888 1/20 0.42
▸ GOT1 P17174 1/20 0.42
▸ PIM1 P11309 1/20 0.42
▸ PIM3 Q86V86 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30386673 0.88 STING1 (0.72) STING1MTOREPHX2GOT1
SCHEMBL28991332 0.88 STING1 (0.72) STING1MTOREPHX2GOT1
SCHEMBL30196003 0.86 STING1 (0.53) STING1IGF1RRIPK1LYNKIT
SCHEMBL23207770 0.86 STING1 (0.53) STING1IGF1RRIPK1LYNKIT
SCHEMBL23207917 0.85 STING1 (0.65) STING1MTORRIPK1EPHX2KIT
SCHEMBL23208193 0.85 STING1 (0.65) STING1MTORIGF1REPHX2GOT1
SCHEMBL30195938 0.85 STING1 (0.65) STING1MTORRIPK1EPHX2KIT
SCHEMBL23208192 0.85 STING1 (0.67) STING1MTORIGF1RRIPK1EPHX2
SCHEMBL23208059 0.83 STING1 (0.62) STING1RIPK1EPHX2LYNKIT
SCHEMBL22803837 0.83 STING1 (0.77) STING1MTOREPHX2GOT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-01-05 — — US disclosed
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-01-05 — — US disclosed
WO-2021067801-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2021-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 STING1 1/4885MTOR 1583/4885IGF1R 2527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback